Meet Us at the 16th Annual World ADC San Diego

The ADC momentum has continued to dominate the oncology field throughout 2024, with the long-awaited approval of ImmunoGen’s ELAHERE – the 9th ADC to be approved in just three years. To add to the excitement, this incredible breakthrough is the first ADC for platinum-resistant ovarian cancer, proving their potential for treatments beyond breast cancer.

Whether you have just ventured into the ADC space or are an ADC guru, the 15th World ADC San Diego had you covered. It accompanied attendees from early discovery to late-stage manufacturing and regulatory challenges, this meeting was designed with one aim in mind: to maximize the therapeutic window of your ADC, and propel ADCs to become life-changing, front-line treatments for oncology patients.

With over 800 world-leading ADC experts in attendance including Daiichi Sankyo, ImmunoGen, AbbVie, Gilead Sciences, and Seagen, this is set to be the biggest-ever convergence of the ADC community yet and you cannot afford to miss it!

Drop by our booth if you will be attending the 16th Annual World ADC San Diego! Our specialists are excited to meet our customers face-to-face to discuss how Creative Biolabs can help develop and optimize your ADC discovery. Feel free to leave your contact information and tell us your partnering needs!